FUNCTIONALIZED ERYTHROID CELLS Russian patent published in 2022 - IPC C12N5/78 A61K35/18 

FIELD: cell biology; genetic engineering.

SUBSTANCE: present invention relates to the field of cell biology and genetic engineering, in particular to methods for the production of a denuclearized erythroid cell covalently bound with exogenous polypeptide, where the specified cell and the specified polypeptide are covalently bound by means of a click chemistry reaction. For the implementation of methods according to the present invention, first, a denuclearized erythroid cell covalently bound with the first chemical fragment by means of a click chemistry reaction is obtained. At the same time, the cell is not obtained by a method, which includes bringing it or its precursor in a contact with sugar, and the first chemical fragment is capable of forming a covalent bond with the second chemical fragment by means of the click chemistry reaction. Then, an activated agent is obtained, containing exogenous polypeptide covalently bound with the second chemical fragment. After that, the denuclearized erythroid cell is brought into contact with the activated agent. At the same time, the denuclearized erythroid cell does not have a sequence created using a reaction with participation of sortase. The click chemistry reaction does not require a catalyst in the form of a copper ion. The specified exogenous polypeptide is an enzyme, antibody, antigen, chemokine, or cytokine.

EFFECT: present invention allows for the improvement of methods for the production of cells containing exogenous polypeptides, which can be used for the treatment of different diseases.

42 cl, 14 dwg, 12 tbl, 27 ex